Advicenne

Advicenne is dedicated to pushing boundaries in the fields of formulation and clinical research. ADV7103, which is tasteless and simple to administer, will be introduced in compact sizes to allow for adaptable and personalized dosing, ensuring that groundbreaking therapies for rare illnesses are accessible to individuals of every generation. The company's headquarters are situated in Nîmes, France, and it was publicly listed on the Euronext Paris stock exchange in December 2017.

Sites

Advicenne S.A.

Country

France

City

Paris

Address

Rue du Faubourg Saint-Honoré 262, 75008